Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 137.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,245 shares of the biopharmaceutical company's stock after acquiring an additional 1,880 shares during the period. Siemens Fonds Invest GmbH's holdings in Alnylam Pharmaceuticals were worth $764,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Larson Financial Group LLC boosted its holdings in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $33,000. Colonial Trust Co SC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $35,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Finally, IFP Advisors Inc raised its position in Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 47 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on ALNY. Needham & Company LLC restated a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Royal Bank of Canada raised their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research report on Friday, March 21st. HC Wainwright reiterated a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $280.00 to $328.00 in a research note on Monday, March 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $319.17.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares of the company's stock, valued at $3,240,344.36. This represents a 10.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,017,271.63. The trade was a 11.44% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $285.31 on Friday. The company has a market cap of $37.20 billion, a P/E ratio of -131.48 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a twelve month low of $146.79 and a twelve month high of $304.39. The company's 50-day moving average price is $253.73 and its 200-day moving average price is $253.58. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. The company's revenue was up 20.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.16) EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.